文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

中国晚期非小细胞肺癌患者紫杉醇个体化药代动力学指导给药的随机研究

Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer.
PubMed 文献 · Br J Clin Pharmacol · 2019-06-14

这项前瞻性随机研究纳入319例中国IIIB/IV期非小细胞肺癌初治患者,比较药代动力学(PK)指导与体表面积(BSA)指导的紫杉醇给药。PK指导组显著降低4级血液学毒性(15% vs 24%,P=.004)和≥2级神经毒性(8% vs 21%,P=.005),客观缓解率和总生存无显著差异。

要点

  • PK指导紫杉醇给药可显著降低4级血液学毒性和≥2级神经毒性。
  • PK组平均紫杉醇剂量和暴露量低于BSA组,疗效未受影响。
  • 两组客观缓解率和总生存相似,PK组无进展生存略优。

核心结论

  • PK指导的紫杉醇给药显著降低4级血液学毒性和≥2级神经毒性,且不影响临床结局。

研究设计与样本

  • 前瞻性随机研究,纳入319例中国IIIB/IV期非小细胞肺癌一线化疗患者。
  • 患者随机接受卡铂联合紫杉醇,起始剂量175 mg/m2,后续按BSA或PK指导给药,PK目标为紫杉醇血浆浓度0.05 μmol/L以上时间(PTXTc>0.05)26至31小时。
  • 主要安全性终点为4级血液学毒性,次要终点包括神经毒性、客观缓解率、无进展生存和总生存。

主要发现

  • 275例(86%)完成≥2周期化疗(BSA组140例,PK组135例)。
  • 第1周期相同紫杉醇剂量下,平均PTXTc>0.05为37小时(范围18-57小时)。
  • 第2-4周期,PK组平均紫杉醇剂量和暴露量显著低于BSA组(128 vs 161 mg/m2,P<.0001;29 vs 35小时,P<.0001)。
  • PK指导显著降低4级血液学毒性累积发生率(15% vs 24%,P=.004)、4级中性粒细胞减少(15% vs 23%,P=.009)和≥2级神经毒性(8% vs 21%,P=.005)。
  • 客观缓解率(32% vs 26%,P=.28)和总生存(21.0 vs 24.0个月,P=.815)两组相似,无进展生存PK组略优(4.67 vs 4.17个月,P=.026)。

关键数值与推荐

  • PK指导目标为PTXTc>0.05在26至31小时之间。
  • 紫杉醇起始剂量175 mg/m2,联合卡铂每3周一次。

临床怎么用

  • 对中国晚期非小细胞肺癌患者,可考虑采用PK指导的紫杉醇给药以降低血液学和神经毒性。
  • PK指导给药可在不损害疗效的前提下减少紫杉醇剂量和暴露量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: This prospective, randomized study was initiated to assess the impact of pharmacokinetically (PK)-guided paclitaxel (PTX) dosing on toxicity and efficacy compared with body-surface area (BSA)-based dosing in Chinese non-small cell lung cancer patients. METHODS: A total of 319 stage IIIB/IV non-small cell lung cancer patients receiving first-line chemotherapy were enrolled. Patients were randomized to receive 3-weekly carboplatin plus PTX at a starting dose of 175 mg/m2 with subsequent PTX dosing based on either BSA or PK-guided dosing targeting time above a PTX plasma concentration of 0.05 μmol/L (PTXTc > 0.05 ) between 26 and 31 hours. The primary safety endpoint was grade 4 haematological toxicity. The secondary endpoints were neuropathy, objective response rate, progression-free survival and overall survival. RESULTS: In total, 275 (86%) patients completed ≥2 cycles of chemotherapy (140 in BSA arm and 135 in PK arm). In cycle 1, with the same PTX dose, average PTXTc > 0.05 was 37 hours (range = 18-57 hours). Over cycles 2-4, patients in the PK arm had significantly lower average PTX doses and exposure compared with the BSA arm (128 vs 161 mg/m2 , P < .0001 and 29 vs 35 hours, P < .0001). PK-guided dosing significantly reduced the cumulative incidence of grade 4 haematological toxicity (15% vs 24%, P = .004), grade 4 neutropenia (15% vs 23%, P = .009) and grade ≥ 2 neuropathy (8% vs 21%, P = .005). Objective response rate (32% vs 26%, P = .28) and overall survival (21.0 vs 24.0 months, P = .815) were similar in PK and BSA arms. Progression-free survival was slightly improved in PK arm (4.67 vs 4.17 months, P = .026). CONCLUSION: PK-guided PTX dosing significantly reduced grade 4 haematological toxicities and grade ≥ 2 neuropathy without an adverse impact on clinical outcomes.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang J, Zhou F, Qi H, et al. Randomized study of individualized pharmacokinetically-guided dosing of paclitaxel compared with body-surface area dosing in Chinese patients with advanced non-small cell lung cancer. Br J Clin Pharmacol. 2019. PMID: 31077432. doi:10.1111/bcp.13982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。